CAL02
Sponsors
Eagle Pharmaceuticals Inc., Eagle Pharmaceuticals, Inc.
Conditions
Pneumonia, BacterialSEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
Phase 2
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
Active, not recruitingNCT05776004
Start: 2023-07-22End: 2026-09-07Target: 276Updated: 2026-01-28
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAL02 ADMINISTERED INTRAVENOUSLY IN ADDITION TO STANDARD OF CARE IN SUBJECTS WITH SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
SuspendedCTIS2022-502049-91-00
Start: 2023-09-26Target: 81Updated: 2025-09-24